People and Places

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Dr. Richard Schilsky, Dr. Edward Pan, Pam Kedziera

Dr. Richard Schilsky

Richard L. Schilsky, MD, associate dean for clinical research at the University of Chicago Pritzker School of Medicine, has been elected president of the American Society of Clinical Oncology for the 2008-2009 term. He will be inducted as president-elect at ASCO's 43rd Annual Meeting in June 2007. Dr. Schilsky's interests include GI cancers, cancer pharmacology, and drug development.

Dr. Edward Pan

The Orlando campus of M.D. Anderson has added neuro-oncologist Edward Pan, MD, to its staff. Dr. Pan comes to M.D. Anderson from the Florida Hospital Cancer Institute where he was co-medical director of neuro-oncology. Prior to that appointment, he was on faculty as a clinical instructor for the Brain Tumor Research Center at the University of California, San Francisco.

Pam Kedziera

Fox Chase Cancer Center has named Pam Kedziera, RN, MSN, ACON, as clinical director of the center's pain and palliative care program. In her new role, she will help lead expansion of the pain management center into a broader focused program while continuing to direct the staff and programs offered at the center. Ms. Kedziera has been affiliated with Fox Chase since 1980.

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content